immunosuppressive efficacy

CS 2100 (1-[[4-Ethyl-5-[5-(4-phenoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-thienyl]methyl]-3-azetidinecarboxylic acid) is an S1P1 agonist.

SS47, a PROTAC-based HPK1 degrader, induces proteasome-mediated HPK1 degradation and significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies [1].

MT204 is a humanized IgG1 antibody inhibitor that targets IL-2 from human and rhesus monkey sources. It prevents soluble IL-2 from binding to the intermediate-affinity IL-2 receptor and blocks IL-2 bound to CD25 from interacting with the high-affinity IL-2 receptor. In rhesus monkey allogeneic skin transplant models, MT204 shows excellent tolerability and potent immunosuppressive activity. With linear pharmacokinetics, a reasonable serum half-life, and signs of good safety and efficacy, MT204 holds promise for use in immunotherapy.